Atlas Trials

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Clinical trial NCT02429375 · COMPLETED

Trial details

NCT number
NCT02429375
Sponsor
Memorial Sloan Kettering Cancer Center
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Hodgkin Lymphoma
Start date
2015-04-22
Primary completion
2021-02-17
Enrollment
7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.